Host-Virus Interactions and Antiviral Immunity: Emerging Mechanisms, Therapeutic Targets, and Clinical Perspectives
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Pharaoh Fellow Mwale und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Viral disease reflects dynamic interactions between viral replication, host-cell dependencies, antiviral immunity and tissue-specific environments. Despite advances in direct-acting antivirals, immune evasion, persistent infection, drug resistance and immune-mediated tissue injury remain major therapeutic challenges.
Aim
This review develops an integrated framework linking host–virus mechanisms to therapeutic vulnerabilities and clinical decision-making, with an emphasis on precision antiviral medicine.
Methods
This narrative review synthesises original experimental and clinical research on viral entry and replication, host dependency factors, intrinsic restriction, innate immune sensing, interferon signalling, adaptive immunity, viral immune evasion and emerging antiviral interventions. Mechanistic, preclinical and clinical evidence is examined to connect biological processes with therapeutic opportunities and translational limitations.
Results
Host–virus interactions expose vulnerabilities involving viral enzymes, cellular entry, host metabolism, intracellular trafficking, immune antagonism and antigen presentation. Direct-acting antivirals, host-directed therapies, neutralising antibodies, nucleic-acid therapeutics and immunomodulatory approaches provide complementary intervention strategies. Their effectiveness, however, depends on the evolving relationship between viral susceptibility, treatment timing, tissue drug exposure, viral evolution and host immune competence. A central implication is that therapeutic selection should extend beyond viral burden to identify the dominant virus–host dependency at each infection stage. Integrating viral kinetics with immune function, tissue involvement and organ injury may help distinguish uncontrolled replication from persistent infection, immune dysfunction or immunopathology, each of which may require a different therapeutic emphasis.
Conclusion
This review frames precision antiviral medicine as a dynamic process of matching treatment to the prevailing biological vulnerability rather than relying on a uniform, virus-centred approach. Combining longitudinal biomarkers with functional genomics and single-cell profiling could improve identification of context-dependent therapeutic targets and support more individualised treatment. Prospective clinical studies are needed to validate this framework and establish whether integrated biological assessment improves treatment selection and patient outcomes.
Zitieren
APA
Mwale, P. F., Kao, C. L., & Chisaka, J. W. (2026). Host-Virus Interactions and Antiviral Immunity: Emerging Mechanisms, Therapeutic Targets, and Clinical Perspectives. Medical Research Archives. https://doi.org/10.18103/mra.2026.0743
Vancouver
Mwale PF, Kao CL, Chisaka JW. Host-Virus Interactions and Antiviral Immunity: Emerging Mechanisms, Therapeutic Targets, and Clinical Perspectives. Medical Research Archives. 2026. doi:10.18103/mra.2026.0743
BibTeX
@article{Mwale2026,
author = {Mwale, Pharaoh Fellow and Kao, Chieh Ling and Chisaka, Joseph Wangisani},
title = {Host-Virus Interactions and Antiviral Immunity: Emerging Mechanisms, Therapeutic Targets, and Clinical Perspectives},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0743}
}
EUVIMED